Determination of saliva trough levels for monitoring voriconazole therapy in immunocompromised children and adults

Therapeutic Drug Monitoring

Volumn 32, Issue 2, 2010, Pages 194-199

  Michael, Claudia ^a   Bierbach, Uta ^b   Frenzel, Katrin ^b   Lange, Thoralf ^a   Basara, Nadezda ^a   Niederwieser, Dietger ^a   Mauz Körholz, Christine ^c   Preiss, Rainer ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

S P ratio; Saliva; Therapeutic drug monitoring; Trough level; Voriconazole

Indexed keywords

VORICONAZOLE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SALIVA LEVEL; FEMALE; HUMAN; IMMUNOCOMPROMISED PATIENT; LOADING DRUG DOSE; MALE; MYCOSIS; PRIORITY JOURNAL; RELIABILITY; AGE; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MYCOSES; PHYSIOLOGY; PRESCHOOL CHILD; PROCEDURES; SALIVA;

ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; MYCOSES; PYRIMIDINES; SALIVA; TRIAZOLES; VORICONAZOLE;

EID: 77950289233     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181cff20d     Document Type: Article

References (35)

1. Cuenca-Estrella M, Rodríguez-Tudela JR, Mellado E, et al. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother. 1998;42:531-533.
2. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol. 1998;36: 198-202.
3. Chandrasekar PH, Manavathu E. Voriconazole: a second-generation triazole. Drugs Today (Barc). 2001;37:135-148.
4. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia. 2001; 150:101-115.
5. Espinel-Ingroff A, Canton E, Gibbs D, et al. Correlation of Neo-Sensitabs tablet diffusion assay on three media, with CLSI broth microdilution M27-A2 and disk diffusion M44-A methods for susceptibility testing of Candida spp. and Cryptococcus neoformans, with amphotericin b, caspo-fungin, fluconazole, itraconazole, and voriconazole. J Clin Microbiol. 2007;45:858-864.
6. Clancy CJ, Nguyen MH. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis. 1998;17:573-575.
7. McGinnis MR, Pasarell L, Sutton DA, et al. In vitro activity of voriconazole against selected fungi. Med Mycol. 1998;36:239-242.
8. Perfect JR, Marr KA, Walsh JT, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003; 36:1122-1131.
9. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327-360.
10. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
11. Roffey SJ, Cole S, Comby P, et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos. 2003; 31:731-741.
12. Lazarus HM, Blumer JL, Yanovich S, et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol. 2002;42:395-402.
13. Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46:2546-2553.
14. Andes D, Marchillo K, Stamstad T, et al. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother. 2003;47:3165-3169.
15. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;24:563-571.
16. US Food and Drug Administration. Background Document for the Antiviral Drug Products Advisory Committee Meeting October 4, 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2- 02-FDA-voriconazole.pdf; page 31. Accessed July 10, 2009.
17. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201-211.
18. Tan K, Brayshaw N, Tomaszewski K, et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006;46:235-243.
19. Boyd AE, Modi S, Howard SJ, et al. Adverse reactions to voriconazole. Clin Infect Dis. 2004;39:1241-1244.
20. Lutsar I, Hodges MR, Tomaszewski K, et al. Safety of voriconazole and dose individualization. Clin Infect Dis. 2003;36:1087-1088.
21. Ikeda Y, Umemura K, Kondo K, et al. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther. 2004; 75:587-588.
22. Kirk JK, Dupuis RE, Miles MV, et al. Salivary theophylline monitoring: reassessment and clinical considerations. Ther Drug Monit. 1994;16: 58-66.
23. Kaufman E, Lamster IB. The diagnostic applications of saliva\a review. Crit Rev Oral Biol Med. 2002;13:197-212.
24. Jusko WJ, Milsap RL. Pharmacokinetic principles of drug distribution in saliva. Ann N Y Acad Sci. 1993;694:36-47.
25. Drobitch RK, Svensson CK. Therapeutic drug monitoring in saliva. An update. Clin Pharmacokinet. 1992;23:365-379.
26. Haeckel R, Hänecke P. Application of saliva for drug monitring. An in vivo model for transmembrane transport. Eur J Clin Chem Clin Biochem. 1996;34:171-191.
27. Adams AI, Morimoto LN, Meneghini LZ, et al. Treatment of invasive fungal infections: stability of voriconazole infusion solutions in PVC bags. Braz J Infect Dis. 2008;12:400-404.
28. Michael C, Teichert J, Preiss R. Determination of voriconazole in human plasma and saliva using high-performance liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;865:74-80.
29. Brüggemann RJ, Donnelly JP, Aarnoutse RE, et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit. 2008;30:403-411.
30. Haeckel R. Factors influencing the saliva/plasma ratio of drugs. Ann NY Acad Sci. 1993;694:128-142.
31. Derendorf H, Rohdewald P, Möllmann H, et al. Pharmacokinetics of prednisolone after high doses of prednisolone hemisuccinate. Biopharm Drug Dispos. 1985;6:423-432.
32. Höld KM, De Boer D, Zuidema J, et al. Evaluation of the Salivette as sampling device for monitoring b-adrenoceptor blocking drugs in saliva. J Chromatogr B Biomed Appl. 1995;663:103-110.
33. Wood JH, Flora KP, Narasimhachari N, et al. Dependence of salivary drug concentration on salivary flow rate. Methods Find Exp Clin Pharmacol. 1982;4:255-260.
34. Klitgaard NA, Kristensen O. Use of saliva for monitoring oxcarbazepine therapy in epileptic patients. Eur J Clin Pharmacol. 1986;31:91-94.
35. Posti J. Saliva-plasma drug concentration ratios during absorption: theoretical considerations and pharmacokinetic implications. Pharm Acta Helv. 1982;57:83-92.